A Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) with VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants with Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy : A Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) with VELCADE, Lenalidomide, and Dexamethasone (VRd) in Subjects with Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
| Medienart: |
|
|---|
Klinische Studie| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
WHO International Clinical Trials Registry Platform - (2021) vom: 27. Dez. Zur Gesamtaufnahme - year:2021 |
|---|
| Sprache: |
Englisch |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
610 |
|---|
| Anmerkungen: |
WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 19-10-2018, Last updated: 2022-11-24 |
|---|
| ICTRP ID: |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
WHO005801613 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | WHO005801613 | ||
| 003 | DE-627 | ||
| 005 | 20230425183730.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210507s2021 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)WHO005801613 | ||
| 035 | |a (UBBS_Klinische_Studien_WHO)JPRN-JapicCTI-184162 | ||
| 035 | |a (UBBS_Klinische_Studien_WHO)NCT03652064 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a A Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) with VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants with Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy |b A Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) with VELCADE, Lenalidomide, and Dexamethasone (VRd) in Subjects with Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 19-10-2018, Last updated: 2022-11-24 | ||
| 650 | 4 | |a Medical Condition: Multiple Myeloma | |
| 650 | 4 | |a Study Type: Interventional | |
| 650 | 4 | |a Recruitment Status: Completed | |
| 650 | 4 | |a 610 | |
| 773 | 0 | 8 | |i Enthalten in |t WHO International Clinical Trials Registry Platform |g (2021) vom: 27. Dez. |
| 773 | 1 | 8 | |g year:2021 |g day:27 |g month:12 |
| 856 | 4 | 0 | |u https://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-184162 |z kostenfrei |3 Volltext |
| 912 | |a GBV_CTG | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2021 |b 27 |c 12 | ||